In the STEP-1 trial (N=1,961), gastrointestinal adverse events were the most common side effect category, reported by 74.2% of semaglutide participants versus 47.9% on placebo [2]
Non-incretin options also appear in patient discussions, including phentermine, bariatric surgery, diet changes, and physical activity programs
Products like Ozempic and Wegovy, which contain semaglutide, have faced significant shortages, leading to approximately 11.1% of patients switching between different GLP-1 therapies within their first year of treatment
10.1007/s10384-004-0121-8
This knowledge arms you with specific questions to ask your doctor and helps you advocate for a more thorough investigation, moving you from a place of uncertainty to empowered action